6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
section	NN	section	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

Suicidal	NNP	suicidal	suicidal	suicid	N	B-AdverseReaction
Behavior	NNP	behavior	behavior	behavior	N	I-AdverseReaction
and	CC	and	and	and	N	O
Ideation	NNP	ideation	ideation	ideat	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Dermatologic	NNP	dermatologic	dermatologic	dermatolog	N	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Drug	NNP	drug	drug	drug	N	B-AdverseReaction
Reaction	NNP	reaction	reaction	reaction	N	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
Eosinophilia	NNP	eosinophilia	eosinophilia	eosinophilia	Y	I-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
Systemic	NNP	systemic	systemic	system	N	I-AdverseReaction
Symptoms	NNP	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
)	)	)	)	)	N	O
Multiorgan	NNP	multiorgan	multiorgan	multiorgan	N	B-AdverseReaction
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
Reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
Angioedema	NNP	angioedema	angioedema	angioedema	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Hyponatremia	NNP	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Neurological	JJ	neurological	neurological	neurolog	N	B-AdverseReaction
Adverse	NNP	adverse	adverse	advers	N	I-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

Drug	NN	drug	drug	drug	N	B-AdverseReaction
Induced	NNP	induced	induced	induc	N	I-AdverseReaction
Liver	NNP	liver	liver	liver	N	I-AdverseReaction
Injury	NNP	injury	injury	injuri	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)]	NN	)]	)]	)]	N	O

Abnormal	NNP	abnormal	abnormal	abnorm	N	B-AdverseReaction
Thyroid	NNP	thyroid	thyroid	thyroid	N	I-AdverseReaction
Function	NNP	function	function	function	N	I-AdverseReaction
Tests	VBZ	tests	test	test	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
,	,	,	,	,	N	O
ataxia	NN	ataxia	ataxia	ataxia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Sunovion	NNP	sunovion	sunovion	sunovion	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
737	CD	737	737	737	N	O
-	:	-	-	-	N	O
7226	CD	7226	7226	7226	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
partial	JJ	partial	partial	partial	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
seizures	NNS	seizures	seizure	seizur	Y	O
[	VBP	[	[	[	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
365	CD	365	365	365	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
225	CD	225	225	225	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
longer	JJR	longer	longer	longer	N	O
than	IN	than	than	than	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
134	CD	134	134	134	N	O
for	IN	for	for	for	N	O
longer	JJR	longer	longer	longer	N	O
than	IN	than	than	than	N	O
24	CD	24	24	24	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
95%	CD	95%	95%	95%	N	O
were	VBD	were	were	were	N	O
between	IN	between	between	between	N	O
18	CD	18	18	18	N	O
and	CC	and	and	and	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
old	JJ	old	old	old	N	O
;	:	;	;	;	N	O
48%	CD	48%	48%	48%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
84%	CD	84%	84%	84%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
.	.	.	.	.	N	O

Across	NNP	across	across	across	N	O
controlled	VBD	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
partial	JJ	partial	partial	partial	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
seizures	NNS	seizures	seizure	seizur	Y	O
,	,	,	,	,	N	O
1195	CD	1195	1195	1195	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
586	CD	586	586	586	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
longer	JJR	longer	longer	longer	N	O
than	IN	than	than	than	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
462	CD	462	462	462	N	O
for	IN	for	for	for	N	O
longer	JJR	longer	longer	longer	N	O
than	IN	than	than	than	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
controlled	VBD	controlled	controlled	control	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
therapy	NN	therapy	therapy	therapi	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
partial	JJ	partial	partial	partial	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
seizures	NNS	seizures	seizure	seizur	Y	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
Study	NNP	study	study	studi	N	O
4	CD	4	4	4	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
1021	CD	1021	1021	1021	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
approximately	RB	approximately	approximately	approxim	N	O
95%	CD	95%	95%	95%	N	O
were	VBD	were	were	were	N	O
between	IN	between	between	between	N	O
18	CD	18	18	18	N	O
and	CC	and	and	and	N	O
60	CD	60	60	60	N	O
years	NNS	years	year	year	N	O
old	JJ	old	old	old	N	O
,	,	,	,	,	N	O
approximately	RB	approximately	approximately	approxim	N	O
50%	CD	50%	50%	50%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
approximately	RB	approximately	approximately	approxim	N	O
80%	CD	80%	80%	80%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
.	.	.	.	.	N	O

Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O
Historical	NNP	historical	historical	histor	N	O
Control	NNP	control	control	control	N	O
Trials	NNP	trials	trial	trial	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
13%	CD	13%	13%	13%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
1200	CD	1200	1200	1200	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
1600	CD	1600	1600	1600	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
trials	NNS	trials	trial	trial	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
result	NN	result	result	result	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
on	IN	on	on	on	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
)	)	)	)	)	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
was	VBD	was	wa	wa	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
observed	VBN	observed	observed	observ	N	O
and	CC	and	and	and	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
in	IN	in	in	in	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
include	VB	include	include	includ	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
control	NN	control	control	control	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
causality	NN	causality	causality	causal	N	O
could	MD	could	could	could	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
all	DT	all	all	all	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
lower	JJR	lower	lower	lower	N	O
incidences	NNS	incidences	incidence	incid	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
AED	NNP	aed	aed	a	N	O
Withdrawal	NNP	withdrawal	withdrawal	withdraw	N	O
Phase	NNP	phase	phase	phase	N	O
and	CC	and	and	and	N	O
Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O
Phase	NNP	phase	phase	phase	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
Titration	NNP	titration	titration	titrat	N	O
Phase	NNP	phase	phase	phase	N	O
.	.	.	.	.	N	O

Adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
Therapy	NNP	therapy	therapy	therapi	N	O
Controlled	NNP	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
therapy	NN	therapy	therapy	therapi	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
Study	NNP	study	study	studi	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
result	NN	result	result	result	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
14%	CD	14%	14%	14%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
800	CD	800	800	800	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
25%	CD	25%	25%	25%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
1200	CD	1200	1200	1200	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
7%	CD	7%	7%	7%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
descending	VBG	descending	descending	descend	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
frequency	NN	frequency	frequency	frequenc	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
ataxia	NN	ataxia	ataxia	ataxia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysarthria	NN	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
800	CD	800	800	800	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
1200	CD	1200	1200	1200	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
dizziness	JJ	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
,	,	,	,	,	N	O
ataxia	NN	ataxia	ataxia	ataxia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
gives	VBZ	gives	give	give	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
partial	JJ	partial	partial	partial	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
seizures	NNS	seizures	seizure	seizur	Y	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
which	WDT	which	which	which	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
was	VBD	was	wa	wa	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
during	IN	during	during	dure	N	O
titration	NN	titration	titration	titrat	N	O
were	VBD	were	were	were	N	O
less	JJR	less	le	less	N	O
frequent	JJ	frequent	frequent	frequent	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
began	VBD	began	began	began	N	O
therapy	NN	therapy	therapy	therapi	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
initial	JJ	initial	initial	initi	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
for	IN	for	for	for	N	O
1	CD	1	1	1	N	O
week	NN	week	week	week	N	O
and	CC	and	and	and	N	O
then	RB	then	then	then	N	O
increased	VBD	increased	increased	increas	N	O
to	TO	to	to	to	N	O
800	CD	800	800	800	N	O
mg	NNS	mg	mg	mg	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
initiated	VBD	initiated	initiated	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
at	IN	at	at	at	N	O
800	CD	800	800	800	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Incidence	NNP	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
Pooled	NNP	pooled	pooled	pool	N	O
Controlled	NNP	controlled	controlled	control	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNP	trials	trial	trial	N	O
of	IN	of	of	of	N	O
Adjunctive	NNP	adjunctive	adjunctive	adjunct	N	O
Therapy	NNP	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
Adults	NNP	adults	adult	adult	N	O
(	(	(	(	(	N	O
Events	NNP	events	event	event	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
800	CD	800	800	800	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
1200	CD	1200	1200	1200	N	O
mg	NN	mg	mg	mg	N	O
Dose	NNP	dose	dose	dose	N	O
Group	NNP	group	group	group	N	O
and	CC	and	and	and	N	O
More	JJR	more	more	more	N	O
Frequent	JJ	frequent	frequent	frequent	N	O
Than	NNP	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Group	NNP	group	group	group	N	O
)	)	)	)	)	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O

800	CD	800	800	800	N	O
mg	NN	mg	mg	mg	N	O
1200	CD	1200	1200	1200	N	O
mg	NN	mg	mg	mg	N	O

(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
426	CD	426	426	426	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
415	CD	415	415	415	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
410	CD	410	410	410	N	O
)	)	)	)	)	N	O

Ear	NN	ear	ear	ear	N	O

and	CC	and	and	and	N	O
labyrinth	JJ	labyrinth	labyrinth	labyrinth	N	O
disorders	NNS	disorders	disorder	disord	N	O
Vertigo	VBP	vertigo	vertigo	vertigo	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
6	CD	6	6	6	N	O

Eye	NNP	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
Diplopia	NNP	diplopia	diplopia	diplopia	Y	B-AdverseReaction
Blurred	NNP	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
Visual	NNP	visual	visual	visual	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
211	CD	211	211	211	N	O
962	CD	962	962	962	N	O
1151	CD	1151	1151	1151	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
Vomiting	NNP	vomiting	vomiting	vomit	Y	B-AdverseReaction
Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
Constipation	NNP	constipation	constipation	constip	Y	B-AdverseReaction
Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
Gastritis	NNP	gastritis	gastritis	gastriti	Y	B-AdverseReaction
53311	CD	53311	53311	53311	N	O
1	CD	1	1	1	N	O
1064222	CD	1064222	1064222	1064222	N	O
1610222	CD	1610222	1610222	1610222	N	O
1	CD	1	1	1	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
Gait	NNP	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	VBZ	edema	edema	edema	Y	I-AdverseReaction
42	CD	42	42	42	N	O
11	CD	11	11	11	N	O
4222	CD	4222	4222	4222	N	O
7321	CD	7321	7321	7321	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNP	infestations	infestation	infest	N	O
Urinary	NNP	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
poisoning	NN	poisoning	poisoning	poison	Y	O
and	CC	and	and	and	N	O
procedural	JJ	procedural	procedural	procedur	N	O
complications	NNS	complications	complication	complic	N	O

Fall	NN	fall	fall	fall	Y	B-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hyponatremia	NNP	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
Somnolence	NNP	somnolence	somnolence	somnol	Y	B-AdverseReaction
Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
Ataxia	NNP	ataxia	ataxia	ataxia	Y	B-AdverseReaction
Balance	NNP	balance	balance	balanc	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
Tremor	NNP	tremor	tremor	tremor	Y	B-AdverseReaction
Dysarthria	NNP	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction
Memory	NNP	memory	memory	memori	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
Nystagmus	NNP	nystagmus	nystagmus	nystagmu	Y	B-AdverseReaction
9892	CD	9892	9892	9892	N	O
110	CD	110	110	110	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
201113432111	CD	201113432111	201113432111	201113432111	N	O
281815634222	CD	281815634222	281815634222	281815634222	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
Depression	NNP	depression	depression	depress	Y	B-AdverseReaction
Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
21	CD	21	21	21	N	O
12	CD	12	12	12	N	O
32	CD	32	32	32	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Rash	VBP	rash	rash	rash	Y	B-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
Hypertension	VBP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

Other	JJ	other	other	other	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
Use	NNP	use	use	use	N	O

Compared	VBN	compared	compared	compar	N	O

to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
use	NN	use	use	use	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
slightly	RB	slightly	slightly	slightli	N	O
higher	JJR	higher	higher	higher	N	O
frequencies	NNS	frequencies	frequency	frequenc	N	O
of	IN	of	of	of	N	O
decreases	NNS	decreases	decrease	decreas	N	O
in	IN	in	in	in	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	O
and	CC	and	and	and	N	O
hematocrit	NN	hematocrit	hematocrit	hematocrit	Y	O
,	,	,	,	,	N	O
increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
total	JJ	total	total	total	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
,	,	,	,	,	N	O
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
increases	VBZ	increases	increase	increas	N	O
in	IN	in	in	in	N	O
creatine	JJ	creatine	creatine	creatin	Y	O
phosphokinase	NN	phosphokinase	phosphokinase	phosphokinas	N	O
.	.	.	.	.	N	O

Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Based	VBD	based	based	base	N	O
on	IN	on	on	on	N	O
Gender	NNP	gender	gender	gender	N	O
and	CC	and	and	and	N	O
Race	NNP	race	race	race	N	O

No	DT	no	no	no	N	O
significant	JJ	significant	significant	signific	N	O
gender	NN	gender	gender	gender	N	O
differences	NNS	differences	difference	differ	N	O
were	VBD	were	were	were	N	O
noted	VBN	noted	noted	note	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
few	JJ	few	few	few	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	O
differences	NNS	differences	difference	differ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidences	NNS	incidences	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Suicidal	NNP	suicidal	suicidal	suicid	N	B-AdverseReaction
Behavior	NNP	behavior	behavior	behavior	N	I-AdverseReaction
and	CC	and	and	and	N	O
Ideation	NNP	ideation	ideation	ideat	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Dermatologic	NNP	dermatologic	dermatologic	dermatolog	N	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
Drug	NNP	drug	drug	drug	N	B-AdverseReaction
Reaction	NNP	reaction	reaction	reaction	N	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
Eosinophilia	NNP	eosinophilia	eosinophilia	eosinophilia	Y	I-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
Systemic	NNP	systemic	systemic	system	N	I-AdverseReaction
Symptoms	NNP	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
Reactions	NNPS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
Angioedema	NNP	angioedema	angioedema	angioedema	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
if	IN	if	if	if	N	O
another	DT	another	another	anoth	N	O
cause	NN	cause	cause	caus	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
sodium	NN	sodium	sodium	sodium	Y	O
levels	NNS	levels	level	level	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
or	CC	or	or	or	N	O
patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Neurological	JJ	neurological	neurological	neurolog	N	B-AdverseReaction
Adverse	NNP	adverse	adverse	advers	N	I-AdverseReaction
Reactions	NNPS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	O
,	,	,	,	,	N	O
disturbance	NN	disturbance	disturbance	disturb	N	O
in	IN	in	in	in	N	O
gait	NN	gait	gait	gait	N	O
and	CC	and	and	and	N	O
coordination	NN	coordination	coordination	coordin	N	O
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	O
,	,	,	,	,	N	O
cognitive	JJ	cognitive	cognitive	cognit	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
visual	JJ	visual	visual	visual	N	O
changes	NNS	changes	change	chang	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
driving	NN	driving	driving	drive	N	O
or	CC	or	or	or	N	O
operating	NN	operating	operating	oper	N	O
machinery	NN	machinery	machinery	machineri	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
:	:	:	:	:	N	O
Withdraw	NNP	withdraw	withdraw	withdraw	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
gradually	RB	gradually	gradually	gradual	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
increased	JJ	increased	increased	increas	N	O
seizure	NN	seizure	seizure	seizur	Y	O
frequency	NN	frequency	frequency	frequenc	N	O
and	CC	and	and	and	N	O
status	NN	status	status	statu	N	O
epilepticus	NN	epilepticus	epilepticus	epilepticu	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.6	CD	2.6	2.6	2.6	N	O
,	,	,	,	,	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Drug	NN	drug	drug	drug	N	B-AdverseReaction
Induced	NNP	induced	induced	induc	N	I-AdverseReaction
Liver	NNP	liver	liver	liver	N	I-AdverseReaction
Injury	NNP	injury	injury	injuri	Y	I-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NNP	discontinue	discontinue	discontinu	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	O
or	CC	or	or	or	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
significant	JJ	significant	significant	signific	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Suicidal	NN	suicidal	suicidal	suicid	N	O

Behavior	NNP	behavior	behavior	behavior	N	O
and	CC	and	and	and	N	O
Ideation	NNP	ideation	ideation	ideat	N	O

Antiepileptic	JJ	antiepileptic	antiepileptic	antiepilept	N	O
drugs	NNS	drugs	drug	drug	N	O
(	(	(	(	(	N	O
AEDs	NNP	aeds	aeds	a	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
,	,	,	,	,	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
these	DT	these	these	these	N	O
drugs	NNS	drugs	drug	drug	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
indication	NN	indication	indication	indic	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
any	DT	any	any	ani	N	O
AED	NNP	aed	aed	a	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
indication	NN	indication	indication	indic	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
or	CC	or	or	or	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
,	,	,	,	,	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
unusual	JJ	unusual	unusual	unusu	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
mood	NN	mood	mood	mood	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
.	.	.	.	.	N	O

Pooled	JJ	pooled	pooled	pool	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
199	CD	199	199	199	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
mono	SYM	mono	mono	mono	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
therapy	NN	therapy	therapy	therapi	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
11	CD	11	11	11	N	O
different	JJ	different	different	differ	N	O
AEDs	NNP	aeds	aeds	a	N	O
showed	VBD	showed	showed	show	N	O
that	IN	that	that	that	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
AEDs	NNP	aeds	aeds	a	N	O
had	VBD	had	had	had	N	O
approximately	RB	approximately	approximately	approxim	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
(	(	(	(	(	N	O
adjusted	VBN	adjusted	adjusted	adjust	N	O
Relative	NNP	relative	relative	rel	N	O
Risk	NNP	risk	risk	risk	N	O
1.8	CD	1.8	1.8	1.8	N	O
,	,	,	,	,	N	O
95%	CD	95%	95%	95%	N	O
confidence	NN	confidence	confidence	confid	N	O
interval	NN	interval	interval	interv	N	O
[	NNP	[	[	[	N	O
CI	NNP	ci	ci	ci	N	O
]	NN	]	]	]	N	O
:	:	:	:	:	N	O
1.2	CD	1.2	1.2	1.2	N	O
,	,	,	,	,	N	O
2.7	CD	2.7	2.7	2.7	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thinking	NN	thinking	thinking	think	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
treatment	NN	treatment	treatment	treatment	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
estimated	VBN	estimated	estimated	estim	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
or	CC	or	or	or	N	O
ideation	NN	ideation	ideation	ideat	N	I-AdverseReaction
among	IN	among	among	among	N	O
27	CD	27	27	27	N	O
,	,	,	,	,	N	O
863	CD	863	863	863	N	O
AED	NNP	aed	aed	a	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
0.43%	CD	0.43%	0.43%	0.43%	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.24%	CD	0.24%	0.24%	0.24%	N	O
among	IN	among	among	among	N	O
16	CD	16	16	16	N	O
,	,	,	,	,	N	O
029	CD	029	029	029	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
representing	VBG	representing	representing	repres	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thinking	NN	thinking	thinking	think	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
for	IN	for	for	for	N	O
every	DT	every	every	everi	N	O
530	CD	530	530	530	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
four	CD	four	four	four	N	O
suicides	NNS	suicides	suicide	suicid	N	B-AdverseReaction
in	IN	in	in	in	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	B-Factor
of	IN	of	of	of	N	I-Factor
events	NNS	events	event	event	N	I-Factor
is	VBZ	is	is	is	N	I-Factor
too	RB	too	too	too	N	I-Factor
small	JJ	small	small	small	N	I-Factor
to	TO	to	to	to	N	I-Factor
allow	VB	allow	allow	allow	N	I-Factor
any	DT	any	any	ani	N	I-Factor
conclusion	NN	conclusion	conclusion	conclus	N	I-Factor
about	IN	about	about	about	N	O
drug	NN	drug	drug	drug	N	O
effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
suicide	NN	suicide	suicide	suicid	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
with	IN	with	with	with	N	O
AEDs	NNP	aeds	aeds	a	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
as	RB	as	a	as	N	O
early	RB	early	early	earli	N	O
as	IN	as	a	as	N	O
one	CD	one	one	one	N	O
week	NN	week	week	week	N	O
after	IN	after	after	after	N	O
starting	VBG	starting	starting	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
AEDs	NNP	aeds	aeds	a	N	O
and	CC	and	and	and	N	O
persisted	VBN	persisted	persisted	persist	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
assessed	VBN	assessed	assessed	assess	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
most	JJS	most	most	most	N	O
trials	NNS	trials	trial	trial	N	O
included	VBD	included	included	includ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
analysis	NN	analysis	analysis	analysi	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
extend	VB	extend	extend	extend	N	O
beyond	IN	beyond	beyond	beyond	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	JJ	behavior	behavior	behavior	N	I-AdverseReaction
beyond	IN	beyond	beyond	beyond	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
could	MD	could	could	could	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
generally	RB	generally	generally	gener	N	O
consistent	JJ	consistent	consistent	consist	N	O
among	IN	among	among	among	N	O
drugs	NNS	drugs	drug	drug	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
analyzed	VBD	analyzed	analyzed	analyz	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
finding	NN	finding	finding	find	N	O
of	IN	of	of	of	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
with	IN	with	with	with	N	O
AEDs	NNP	aeds	aeds	a	N	O
of	IN	of	of	of	N	O
varying	VBG	varying	varying	vari	N	O
mechanisms	NNS	mechanisms	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
and	CC	and	and	and	N	O
across	IN	across	across	across	N	O
a	DT	a	a	a	N	O
range	NN	range	range	rang	N	O
of	IN	of	of	of	N	O
indications	NNS	indications	indication	indic	N	O
suggests	VBZ	suggests	suggests	suggest	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
applies	NNS	applies	applies	appli	N	O
to	TO	to	to	to	N	O
all	DT	all	all	all	N	O
AEDs	NNP	aeds	aeds	a	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
indication	NN	indication	indication	indic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
vary	JJ	vary	vary	vari	N	O
substantially	RB	substantially	substantially	substanti	N	O
by	IN	by	by	by	N	O
age	NN	age	age	age	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
-	:	-	-	-	N	O
100	CD	100	100	100	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
analyzed	VBD	analyzed	analyzed	analyz	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
shows	NNS	shows	show	show	N	O
absolute	NN	absolute	absolute	absolut	N	O
and	CC	and	and	and	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
by	IN	by	by	by	N	O
indication	NN	indication	indication	indic	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
evaluated	JJ	evaluated	evaluated	evalu	N	O
AEDs	NNP	aeds	aeds	a	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
Suicidal	NNP	suicidal	suicidal	suicid	N	B-AdverseReaction
Thoughts	NNP	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
Behaviors	NNS	behaviors	behavior	behavior	N	I-AdverseReaction
by	IN	by	by	by	N	O
Indication	NNP	indication	indication	indic	N	O
for	IN	for	for	for	N	O
Antiepileptic	NNP	antiepileptic	antiepileptic	antiepilept	N	O
Drugs	NNP	drugs	drug	drug	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Pooled	NNP	pooled	pooled	pool	N	O
Analysis	NN	analysis	analysis	analysi	N	O

Indication	NNP	indication	indication	indic	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Patients	NNPS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Events	NNS	events	event	event	N	O
Per	IN	per	per	per	N	O
1000	CD	1000	1000	1000	N	O
Patients	NNS	patients	patient	patient	N	O
Drug	JJ	drug	drug	drug	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Events	NNS	events	event	event	N	O
Per	IN	per	per	per	N	O
1000	CD	1000	1000	1000	N	O
Patients	NNS	patients	patient	patient	N	O
Relative	JJ	relative	relative	rel	N	O
Risk	NN	risk	risk	risk	N	O
:	:	:	:	:	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
Drug	NNP	drug	drug	drug	N	O
Patients	NNPS	patients	patient	patient	N	O
Incidence	NNP	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Patients	NNP	patients	patient	patient	N	O
Risk	NNP	risk	risk	risk	N	O
Differences	NNS	differences	difference	differ	N	O
:	:	:	:	:	N	O
Additional	JJ	additional	additional	addit	N	O
Drug	NN	drug	drug	drug	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Events	NNS	events	event	event	N	O
Per	IN	per	per	per	N	O
1000	CD	1000	1000	1000	N	O
Patients	NNS	patients	patient	patient	N	O

Epilepsy	NNP	epilepsy	epilepsy	epilepsi	Y	O
1.0	CD	1.0	1.0	1.0	N	O
3.4	CD	3.4	3.4	3.4	N	O
3.5	CD	3.5	3.5	3.5	N	O
2.4	CD	2.4	2.4	2.4	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
5.7	CD	5.7	5.7	5.7	N	O
8.5	CD	8.5	8.5	8.5	N	O
1.5	CD	1.5	1.5	1.5	N	O
2.9	CD	2.9	2.9	2.9	N	O

Other	JJ	other	other	other	N	O
1.0	CD	1.0	1.0	1.0	N	O
1.8	CD	1.8	1.8	1.8	N	O
1.9	CD	1.9	1.9	1.9	N	O
0.9	CD	0.9	0.9	0.9	N	O

Total	JJ	total	total	total	N	O
2.4	CD	2.4	2.4	2.4	N	O
4.3	CD	4.3	4.3	4.3	N	O
1.8	CD	1.8	1.8	1.8	N	O
1.9	CD	1.9	1.9	1.9	N	O

The	DT	the	the	the	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
the	DT	the	the	the	N	O
absolute	NN	absolute	absolute	absolut	N	O
risk	NN	risk	risk	risk	N	O
differences	NNS	differences	difference	differ	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
for	IN	for	for	for	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
and	CC	and	and	and	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
indications	NNS	indications	indication	indic	N	O
.	.	.	.	.	N	O

Anyone	NN	anyone	anyone	anyon	N	O

considering	VBG	considering	considering	consid	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
AED	NNP	aed	aed	a	N	O
must	MD	must	must	must	N	O
balance	VB	balance	balance	balanc	N	O
this	DT	this	this	thi	N	O
risk	NN	risk	risk	risk	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
untreated	JJ	untreated	untreated	untreat	N	O
illness	NN	illness	illness	ill	N	O
.	.	.	.	.	N	O

Epilepsy	NNP	epilepsy	epilepsy	epilepsi	Y	O
and	CC	and	and	and	N	O
many	JJ	many	many	mani	N	O
other	JJ	other	other	other	N	O
illnesses	NNS	illnesses	illness	ill	N	B-Negation
for	IN	for	for	for	N	I-Negation
which	WDT	which	which	which	N	I-Negation
AEDs	NNP	aeds	aeds	a	N	I-Negation
are	VBP	are	are	are	N	I-Negation
prescribed	VBN	prescribed	prescribed	prescrib	N	I-Negation
are	VBP	are	are	are	N	O
themselves	PRP	themselves	themselves	themselv	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
morbidity	NN	morbidity	morbidity	morbid	N	B-AdverseReaction
and	CC	and	and	and	N	O
mortality	NN	mortality	mortality	mortal	N	B-AdverseReaction
and	CC	and	and	and	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
and	CC	and	and	and	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
.	.	.	.	.	N	O

Should	MD	should	should	should	N	O
suicidal	VB	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
and	CC	and	and	and	N	O
behavior	JJ	behavior	behavior	behavior	N	O
emerge	NN	emerge	emerge	emerg	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
prescriber	NN	prescriber	prescriber	prescrib	N	O
needs	VBZ	needs	need	need	N	O
to	TO	to	to	to	N	O
consider	VB	consider	consider	consid	N	O
whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
given	VBN	given	given	given	N	O
patient	NN	patient	patient	patient	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
illness	NN	illness	illness	ill	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
their	PRP$	their	their	their	N	O
caregivers	NNS	caregivers	caregiver	caregiv	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
families	NNS	families	family	famili	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
informed	VBN	informed	informed	inform	N	O
that	IN	that	that	that	N	O
AEDs	NNP	aeds	aeds	a	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
and	CC	and	and	and	N	O
behavior	NN	behavior	behavior	behavior	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
need	NN	need	need	need	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
alert	JJ	alert	alert	alert	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
or	CC	or	or	or	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
;	:	;	;	;	N	O
any	DT	any	any	ani	N	O
unusual	JJ	unusual	unusual	unusu	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
mood	NN	mood	mood	mood	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
;	:	;	;	;	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
,	,	,	,	,	N	O
behavior	NN	behavior	behavior	behavior	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
thoughts	NNS	thoughts	thought	thought	N	O
about	IN	about	about	about	N	O
self	PRP	self	self	self	N	O
-	:	-	-	-	N	O
harm	NN	harm	harm	harm	N	O
.	.	.	.	.	N	O

Behaviors	NNS	behaviors	behavior	behavior	N	O
of	IN	of	of	of	N	O
concern	NN	concern	concern	concern	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
reported	VBN	reported	reported	report	N	O
immediately	RB	immediately	immediately	immedi	N	O
to	TO	to	to	to	N	O
healthcare	VB	healthcare	healthcare	healthcar	N	O
providers	NNS	providers	provider	provid	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Serious	JJ	serious	serious	seriou	N	O
Dermatologic	NNP	dermatologic	dermatologic	dermatolog	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Serious	JJ	serious	serious	seriou	N	O
dermatologic	JJ	dermatologic	dermatologic	dermatolog	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
SJS	NNP	sjs	sjs	sj	N	B-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
dermatologic	JJ	dermatologic	dermatologic	dermatolog	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
toxic	JJ	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
(	(	(	(	(	N	O
TEN	NNP	ten	ten	ten	Y	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
SJS	NNP	sjs	sjs	sj	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
using	VBG	using	using	use	N	O
oxcarbazepine	NN	oxcarbazepine	oxcarbazepine	oxcarbazepin	N	B-DrugClass
or	CC	or	or	or	N	O
carbamazepine	NN	carbamazepine	carbamazepine	carbamazepin	N	O
which	WDT	which	which	which	N	O
are	VBP	are	are	are	N	O
chemically	RB	chemically	chemically	chemic	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
reporting	NN	reporting	reporting	report	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBD	associated	associated	associ	N	O
with	IN	with	with	with	N	O
oxcarbazepine	NN	oxcarbazepine	oxcarbazepine	oxcarbazepin	N	O
use	NN	use	use	use	N	O
exceeds	VBZ	exceeds	exceeds	exce	N	O
the	DT	the	the	the	N	O
background	NN	background	background	background	N	O
incidence	NN	incidence	incidence	incid	N	O
rate	NN	rate	rate	rate	N	O
estimates	NNS	estimates	estimate	estim	N	O
by	IN	by	by	by	N	O
a	DT	a	a	a	N	O
factor	NN	factor	factor	factor	N	O
of	IN	of	of	of	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
to	TO	to	to	to	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
.	.	.	.	.	N	O

Risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
dermatologic	JJ	dermatologic	dermatologic	dermatolog	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
with	IN	with	with	with	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
use	NN	use	use	use	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	B-Negation
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
dermatologic	JJ	dermatologic	dermatologic	dermatolog	N	O
reaction	NN	reaction	reaction	reaction	N	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
,	,	,	,	,	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
use	NN	use	use	use	N	O
,	,	,	,	,	N	O
unless	IN	unless	unless	unless	N	O
the	DT	the	the	the	N	O
reaction	NN	reaction	reaction	reaction	N	O
is	VBZ	is	is	is	N	O
clearly	RB	clearly	clearly	clearli	N	O
not	RB	not	not	not	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
prior	JJ	prior	prior	prior	N	O
dermatologic	JJ	dermatologic	dermatologic	dermatolog	N	O
reaction	NN	reaction	reaction	reaction	N	O
with	IN	with	with	with	N	O
either	DT	either	either	either	N	O
oxcarbazepine	NN	oxcarbazepine	oxcarbazepine	oxcarbazepin	N	O
or	CC	or	or	or	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Drug	NNP	drug	drug	drug	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
with	IN	with	with	with	N	O
Eosinophilia	NNP	eosinophilia	eosinophilia	eosinophilia	Y	O
and	CC	and	and	and	N	O
Systemic	NNP	systemic	systemic	system	N	O
Symptoms	NNP	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
DRESS	NNP	dress	dress	dress	N	O
)	)	)	)	)	N	O
Multiorgan	NNP	multiorgan	multiorgan	multiorgan	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O

Drug	NNP	drug	drug	drug	N	B-AdverseReaction
Reaction	NNP	reaction	reaction	reaction	N	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
Eosinophilia	NNP	eosinophilia	eosinophilia	eosinophilia	Y	I-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
Systemic	NNP	systemic	systemic	system	N	I-AdverseReaction
Symptoms	NNP	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
also	RB	also	also	also	N	O
known	VBN	known	known	known	N	O
as	IN	as	a	as	N	O
Multiorgan	NNP	multiorgan	multiorgan	multiorgan	N	B-AdverseReaction
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
.	.	.	.	.	N	O

DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
or	CC	or	or	or	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
.	.	.	.	.	N	O

DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
typically	RB	typically	typically	typic	N	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
not	RB	not	not	not	N	O
exclusively	RB	exclusively	exclusively	exclus	N	O
,	,	,	,	,	N	O
presents	NNS	presents	present	present	N	O
with	IN	with	with	with	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
lymphadenopathy	JJ	lymphadenopathy	lymphadenopathy	lymphadenopathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
organ	JJ	organ	organ	organ	N	O
system	NN	system	system	system	N	O
involvement	NN	involvement	involvement	involv	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
,	,	,	,	,	N	O
nephritis	NN	nephritis	nephritis	nephriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
hematological	JJ	hematological	hematological	hematolog	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
,	,	,	,	,	N	O
myocarditis	NN	myocarditis	myocarditis	myocard	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
myositis	NN	myositis	myositis	myositi	Y	B-AdverseReaction
sometimes	RB	sometimes	sometimes	sometim	N	O
resembling	VBG	resembling	resembling	resembl	N	O
an	DT	an	an	an	N	O
acute	JJ	acute	acute	acut	N	O
viral	JJ	viral	viral	viral	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Eosinophilia	NNP	eosinophilia	eosinophilia	eosinophilia	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
often	RB	often	often	often	N	O
present	JJ	present	present	present	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
this	DT	this	this	thi	N	O
disorder	NN	disorder	disorder	disord	N	O
is	VBZ	is	is	is	N	O
variable	JJ	variable	variable	variabl	N	O
in	IN	in	in	in	N	O
its	PRP$	its	it	it	N	O
expression	NN	expression	expression	express	N	O
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
organ	JJ	organ	organ	organ	N	O
systems	NNS	systems	system	system	N	O
not	RB	not	not	not	N	O
noted	VBN	noted	noted	note	N	O
here	RB	here	here	here	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
involved	VBN	involved	involved	involv	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
important	JJ	important	important	import	N	O
to	TO	to	to	to	N	O
note	VB	note	note	note	N	O
that	IN	that	that	that	N	O
early	JJ	early	early	earli	N	O
manifestations	NNS	manifestations	manifestation	manifest	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
or	CC	or	or	or	N	O
lymphadenopathy	JJ	lymphadenopathy	lymphadenopathy	lymphadenopathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
present	JJ	present	present	present	N	O
even	RB	even	even	even	N	O
though	IN	though	though	though	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	B-Negation
evident	JJ	evident	evident	evid	N	I-Negation
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
are	VBP	are	are	are	N	O
present	JJ	present	present	present	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
immediately	RB	immediately	immediately	immedi	N	O
.	.	.	.	.	N	O

APTIOM	NNP	aptiom	aptiom	aptiom	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
and	CC	and	and	and	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
resumed	VBN	resumed	resumed	resum	N	O
if	IN	if	if	if	N	O
an	DT	an	an	an	N	O
alternative	JJ	alternative	alternative	altern	N	O
etiology	NN	etiology	etiology	etiolog	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
cannot	VBP	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
prior	JJ	prior	prior	prior	N	O
DRESS	NNP	dress	dress	dress	N	O
reaction	NN	reaction	reaction	reaction	N	O
with	IN	with	with	with	N	O
either	DT	either	either	either	N	O
oxcarbazepine	NN	oxcarbazepine	oxcarbazepine	oxcarbazepin	N	O
or	CC	or	or	or	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
Angioedema	NNP	angioedema	angioedema	angioedema	Y	O

Rare	JJ	rare	rare	rare	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
.	.	.	.	.	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
angioedema	RB	angioedema	angioedema	angioedema	Y	B-AdverseReaction
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
laryngeal	JJ	laryngeal	laryngeal	laryng	N	B-AdverseReaction
edema	NNS	edema	edema	edema	Y	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
be	VB	be	be	be	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	JJ	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
prior	JJ	prior	prior	prior	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	O
-	:	-	-	-	N	O
type	NN	type	type	type	N	O
reaction	NN	reaction	reaction	reaction	N	O
with	IN	with	with	with	N	O
either	DT	either	either	either	N	O
oxcarbazepine	NN	oxcarbazepine	oxcarbazepine	oxcarbazepin	N	O
or	CC	or	or	or	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	O

Clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
(	(	(	(	(	N	O
sodium	JJ	sodium	sodium	sodium	Y	O
125	CD	125	125	125	N	O
mEq	NN	meq	meq	meq	N	O
L	NNP	l	l	l	N	O
)	)	)	)	)	N	O
can	MD	can	can	can	N	O
develop	VB	develop	develop	develop	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
415	CD	415	415	415	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
800	CD	800	800	800	N	O
mg	NNS	mg	mg	mg	N	O
and	CC	and	and	and	N	O
6	CD	6	6	6	N	O
410	CD	410	410	410	N	O
(	(	(	(	(	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
1200	CD	1200	1200	1200	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
had	VBD	had	had	had	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
serum	NN	serum	serum	serum	N	O
sodium	NN	sodium	sodium	sodium	Y	O
value	NN	value	value	valu	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
125	CD	125	125	125	N	O
mEq	JJ	meq	meq	meq	N	O
L	NNP	l	l	l	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
assigned	VBD	assigned	assigned	assign	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
5.1%	CD	5.1%	5.1%	5.1%	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
)	)	)	)	)	N	O
experienced	VBD	experienced	experienced	experienc	N	O
decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
sodium	NN	sodium	sodium	sodium	Y	I-AdverseReaction
values	NNS	values	value	valu	N	I-AdverseReaction
of	IN	of	of	of	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
10	CD	10	10	10	N	B-Severity
mEq	NNS	meq	meq	meq	N	I-Severity
L.	NNP	l.	l.	l.	N	I-Severity

These	DT	these	these	these	N	O
effects	NNS	effects	effect	effect	N	O
were	VBD	were	were	were	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
and	CC	and	and	and	N	O
generally	RB	generally	generally	gener	N	O
appeared	VBD	appeared	appeared	appear	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
8	CD	8	8	8	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
(	(	(	(	(	N	O
as	RB	as	a	as	N	O
early	RB	early	early	earli	N	O
as	IN	as	a	as	N	O
after	IN	after	after	after	N	O
3	CD	3	3	3	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	JJ	threatening	threatening	threaten	N	I-Severity
complications	NNS	complications	complication	complic	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
(	(	(	(	(	N	O
as	RB	as	a	as	N	O
low	JJ	low	low	low	N	O
as	IN	as	a	as	N	O
112	CD	112	112	112	N	B-Severity
mEq	NNS	meq	meq	meq	N	I-Severity
L	NNP	l	l	l	N	I-Severity
)	)	)	)	)	N	O
including	VBG	including	including	includ	N	O
seizures	NNS	seizures	seizure	seizur	Y	B-AdverseReaction
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	B-Severity
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	B-Severity
gait	NN	gait	gait	gait	N	B-AdverseReaction
instability	NN	instability	instability	instabl	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
injury	NN	injury	injury	injuri	Y	B-AdverseReaction
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
required	VBN	required	required	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
and	CC	and	and	and	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
.	.	.	.	.	N	O

Concurrent	NNP	concurrent	concurrent	concurr	N	O
hypochloremia	NN	hypochloremia	hypochloremia	hypochloremia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
present	JJ	present	present	present	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Depending	VBG	depending	depending	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
may	MD	may	may	may	N	O
need	VB	need	need	need	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
reduced	VBN	reduced	reduced	reduc	N	O
or	CC	or	or	or	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

Hyponatremia	NNP	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Measurement	NN	measurement	measurement	measur	N	O
of	IN	of	of	of	N	O
serum	NN	serum	serum	serum	N	O
sodium	NN	sodium	sodium	sodium	Y	O
and	CC	and	and	and	N	O
chloride	NN	chloride	chloride	chlorid	Y	O
levels	NNS	levels	level	level	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
during	IN	during	during	dure	N	O
maintenance	NN	maintenance	maintenance	mainten	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
is	VBZ	is	is	is	N	O
receiving	VBG	receiving	receiving	receiv	N	O
other	JJ	other	other	other	N	O
medications	NNS	medications	medication	medic	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
decrease	VB	decrease	decrease	decreas	N	O
serum	JJ	serum	serum	serum	N	O
sodium	NN	sodium	sodium	sodium	Y	O
levels	NNS	levels	level	level	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
performed	VBN	performed	performed	perform	N	O
if	IN	if	if	if	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	O
develop	NN	develop	develop	develop	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	O
vomiting	NN	vomiting	vomiting	vomit	Y	O
,	,	,	,	,	N	O
malaise	NN	malaise	malaise	malais	Y	O
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	O
,	,	,	,	,	N	O
lethargy	NN	lethargy	lethargy	lethargi	Y	O
,	,	,	,	,	N	O
confusion	NN	confusion	confusion	confus	Y	O
,	,	,	,	,	N	O
irritability	NN	irritability	irritability	irrit	Y	O
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	O
weakness	NN	weakness	weakness	weak	Y	O
spasms	NN	spasms	spasm	spasm	Y	O
,	,	,	,	,	N	O
obtundation	NN	obtundation	obtundation	obtund	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
increase	VB	increase	increase	increas	N	O
in	IN	in	in	in	N	O
seizure	JJ	seizure	seizure	seizur	Y	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
severity	NN	severity	severity	sever	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Neurological	JJ	neurological	neurological	neurolog	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	O
and	CC	and	and	and	N	O
Disturbance	NNP	disturbance	disturbance	disturb	N	O
in	IN	in	in	in	N	O
Gait	NNP	gait	gait	gait	N	O
and	CC	and	and	and	N	O
Coordination	NNP	coordination	coordination	coordin	N	O

APTIOM	NNP	aptiom	aptiom	aptiom	N	O
causes	VBZ	causes	cause	caus	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
gait	NN	gait	gait	gait	N	I-AdverseReaction
and	CC	and	and	and	N	O
coordination	NN	coordination	coordination	coordin	N	I-AdverseReaction
(	(	(	(	(	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
ataxia	NN	ataxia	ataxia	ataxia	Y	B-AdverseReaction
,	,	,	,	,	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
,	,	,	,	,	N	O
balance	NN	balance	balance	balanc	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
gait	NN	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
,	,	,	,	,	N	O
nystagmus	NN	nystagmus	nystagmus	nystagmu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
coordination	NN	coordination	coordination	coordin	N	I-AdverseReaction
)	)	)	)	)	N	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
26%	CD	26%	26%	26%	N	O
and	CC	and	and	and	N	O
38%	CD	38%	38%	38%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
800	CD	800	800	800	N	O
mg	NNS	mg	mg	mg	N	O
and	CC	and	and	and	N	O
1200	CD	1200	1200	1200	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
12%	CD	12%	12%	12%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Events	NNS	events	event	event	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
gait	NN	gait	gait	gait	N	I-AdverseReaction
and	CC	and	and	and	N	O
coordination	NN	coordination	coordination	coordin	N	I-AdverseReaction
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
often	RB	often	often	often	N	O
serious	JJ	serious	serious	seriou	N	O
in	IN	in	in	in	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
placebo	JJ	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
often	RB	often	often	often	N	O
led	VBN	led	led	led	N	O
to	TO	to	to	to	N	O
study	VB	study	study	studi	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
in	IN	in	in	in	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
placebo	JJ	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0.7%	CD	0.7%	0.7%	0.7%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
titration	NN	titration	titration	titrat	N	O
period	NN	period	period	period	N	O
(	(	(	(	(	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
maintenance	NN	maintenance	maintenance	mainten	N	O
period	NN	period	period	period	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
there	EX	there	there	there	N	O
also	RB	also	also	also	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
60	CD	60	60	60	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
younger	JJR	younger	younger	younger	N	O
adults	NNS	adults	adult	adult	N	O
.	.	.	.	.	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
and	CC	and	and	and	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
also	RB	also	also	also	N	O
occurred	VBD	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
gait	NN	gait	gait	gait	N	I-AdverseReaction
and	CC	and	and	and	N	O
coordination	NN	coordination	coordination	coordin	N	I-AdverseReaction
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
greater	JJR	greater	greater	greater	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
and	CC	and	and	and	N	O
carbamazepine	NN	carbamazepine	carbamazepine	carbamazepin	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
without	IN	without	without	without	N	O
carbamazepine	NN	carbamazepine	carbamazepine	carbamazepin	N	O
(	(	(	(	(	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
37%	CD	37%	37%	37%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

19%	CD	19%	19%	19%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
dosage	NN	dosage	dosage	dosag	N	O
modifications	NNS	modifications	modification	modif	N	O
of	IN	of	of	of	N	O
both	DT	both	both	both	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
and	CC	and	and	and	N	O
carbamazepine	VB	carbamazepine	carbamazepine	carbamazepin	N	O
if	IN	if	if	if	N	O
these	DT	these	these	these	N	O
drugs	NNS	drugs	drug	drug	N	O
are	VBP	are	are	are	N	O
used	VBN	used	used	use	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	O
and	CC	and	and	and	N	O
Fatigue	NNP	fatigue	fatigue	fatigu	Y	O

APTIOM	NNP	aptiom	aptiom	aptiom	N	O
causes	VBZ	causes	cause	caus	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
dependent	NN	dependent	dependent	depend	N	O
increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
malaise	NN	malaise	malaise	malais	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypersomnia	NN	hypersomnia	hypersomnia	hypersomnia	Y	B-AdverseReaction
,	,	,	,	,	N	O
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
lethargy	NN	lethargy	lethargy	lethargi	Y	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
13%	CD	13%	13%	13%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
16%	CD	16%	16%	16%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
800	CD	800	800	800	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
28%	CD	28%	28%	28%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
1200	CD	1200	1200	1200	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
.	.	.	.	.	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
serious	JJ	serious	serious	seriou	N	O
in	IN	in	in	in	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
and	CC	and	and	and	N	O
0	CD	0	0	0	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
led	VBN	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
and	CC	and	and	and	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Cognitive	JJ	cognitive	cognitive	cognit	N	O
Dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O

APTIOM	NNP	aptiom	aptiom	aptiom	N	O
causes	VBZ	causes	cause	caus	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
dependent	NN	dependent	dependent	depend	N	O
increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
cognitive	JJ	cognitive	cognitive	cognit	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
memory	NN	memory	memory	memori	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
attention	NN	attention	attention	attent	N	I-AdverseReaction
,	,	,	,	,	N	O
amnesia	NN	amnesia	amnesia	amnesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
confusional	JJ	confusional	confusional	confusion	N	B-AdverseReaction
state	NN	state	state	state	N	I-AdverseReaction
,	,	,	,	,	N	O
aphasia	NN	aphasia	aphasia	aphasia	Y	B-AdverseReaction
,	,	,	,	,	N	O
speech	NN	speech	speech	speech	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
slowness	NN	slowness	slowness	slow	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
thought	NN	thought	thought	thought	N	I-AdverseReaction
,	,	,	,	,	N	O
disorientation	NN	disorientation	disorientation	disorient	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
psychomotor	NN	psychomotor	psychomotor	psychomotor	N	B-AdverseReaction
retardation	NN	retardation	retardation	retard	N	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
800	CD	800	800	800	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
7%	CD	7%	7%	7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
1200	CD	1200	1200	1200	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
.	.	.	.	.	N	O

Cognitive	JJ	cognitive	cognitive	cognit	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
and	CC	and	and	and	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
led	VBN	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
and	CC	and	and	and	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Cognitive	JJ	cognitive	cognitive	cognit	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Visual	JJ	visual	visual	visual	N	O
Changes	NNS	changes	change	chang	N	O

APTIOM	NNP	aptiom	aptiom	aptiom	N	O
causes	VBZ	causes	cause	caus	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
dependent	NN	dependent	dependent	depend	N	O
increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
events	NNS	events	event	event	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
impaired	JJ	impaired	impaired	impair	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
16%	CD	16%	16%	16%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Eye	JJ	eye	eye	eye	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
in	IN	in	in	in	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
and	CC	and	and	and	N	O
0	CD	0	0	0	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
led	VBN	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
and	CC	and	and	and	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
titration	NN	titration	titration	titrat	N	O
period	NN	period	period	period	N	O
(	(	(	(	(	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
maintenance	NN	maintenance	maintenance	mainten	N	O
period	NN	period	period	period	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
also	RB	also	also	also	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
60	CD	60	60	60	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
(	(	(	(	(	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
younger	JJR	younger	younger	younger	N	O
adults	NNS	adults	adult	adult	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
greater	JJR	greater	greater	greater	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
and	CC	and	and	and	N	O
carbamazepine	NN	carbamazepine	carbamazepine	carbamazepin	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
without	IN	without	without	without	N	O
carbamazepine	NN	carbamazepine	carbamazepine	carbamazepin	N	O
(	(	(	(	(	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
16%	CD	16%	16%	16%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

6%	CD	6%	6%	6%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Events	NNS	events	event	event	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Hazardous	JJ	hazardous	hazardous	hazard	N	O
Activities	NNS	activities	activity	activ	N	O

Prescribers	NNS	prescribers	prescribers	prescrib	N	O
should	MD	should	should	should	N	O
advise	VB	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
against	IN	against	against	against	N	O
engaging	VBG	engaging	engaging	engag	N	O
in	IN	in	in	in	N	O
hazardous	JJ	hazardous	hazardous	hazard	N	O
activities	NNS	activities	activity	activ	N	O
requiring	VBG	requiring	requiring	requir	N	O
mental	JJ	mental	mental	mental	N	O
alertness	NN	alertness	alertness	alert	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
operating	NN	operating	operating	oper	N	O
motor	NN	motor	motor	motor	N	O
vehicles	NNS	vehicles	vehicle	vehicl	N	O
or	CC	or	or	or	N	O
dangerous	JJ	dangerous	dangerous	danger	N	O
machinery	NN	machinery	machinery	machineri	N	O
,	,	,	,	,	N	O
until	IN	until	until	until	N	O
the	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
is	VBZ	is	is	is	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Withdrawal	NNP	withdrawal	withdrawal	withdraw	N	O
of	IN	of	of	of	N	O
AEDs	NNP	aeds	aeds	a	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
antiepileptic	JJ	antiepileptic	antiepileptic	antiepilept	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
withdrawn	VBN	withdrawn	withdrawn	withdrawn	Y	O
gradually	RB	gradually	gradually	gradual	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
increased	JJ	increased	increased	increas	N	O
seizure	NN	seizure	seizure	seizur	Y	O
frequency	NN	frequency	frequency	frequenc	N	O
and	CC	and	and	and	N	O
status	NN	status	status	statu	N	O
epilepticus	NN	epilepticus	epilepticus	epilepticu	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Drug	NNP	drug	drug	drug	N	O
Induced	NNP	induced	induced	induc	N	O
Liver	NNP	liver	liver	liver	N	O
Injury	NNP	injury	injury	injuri	Y	O

Hepatic	JJ	hepatic	hepatic	hepat	N	O
effects	NNS	effects	effect	effect	N	O
,	,	,	,	,	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
mild	NN	mild	mild	mild	N	B-Severity
to	TO	to	to	to	N	I-Severity
moderate	VB	moderate	moderate	moder	N	I-Severity
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
(	(	(	(	(	N	O
3	CD	3	3	3	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
rare	JJ	rare	rare	rare	N	O
cases	NNS	cases	case	case	N	O
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
total	JJ	total	total	total	N	I-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
(	(	(	(	(	N	O
2	CD	2	2	2	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
evaluations	NNS	evaluations	evaluation	evalu	N	O
of	IN	of	of	of	N	O
liver	JJ	liver	liver	liver	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
tests	NNS	tests	test	test	N	O
are	VBP	are	are	are	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
and	CC	and	and	and	N	O
elevated	VBD	elevated	elevated	elev	N	B-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
without	IN	without	without	without	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
obstruction	NN	obstruction	obstruction	obstruct	Y	O
is	VBZ	is	is	is	N	O
generally	RB	generally	generally	gener	N	O
recognized	VBN	recognized	recognized	recogn	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
important	JJ	important	important	import	N	O
predictor	NN	predictor	predictor	predictor	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	B-Severity
liver	JJ	liver	liver	liver	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
.	.	.	.	.	N	O

APTIOM	NNP	aptiom	aptiom	aptiom	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
significant	JJ	significant	significant	signific	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
evidence	NN	evidence	evidence	evid	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Abnormal	NNP	abnormal	abnormal	abnorm	N	O
Thyroid	NNP	thyroid	thyroid	thyroid	N	O
Function	NNP	function	function	function	N	O
Tests	NNS	tests	test	test	N	O

Dose	NNP	dose	dose	dose	N	O
-	:	-	-	-	N	O
dependent	NN	dependent	dependent	depend	N	O
decreases	VBZ	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
T3	NNP	t3	t3	t3	Y	I-AdverseReaction
and	CC	and	and	and	N	O
T4	NNP	t4	t4	t4	Y	I-AdverseReaction
(	(	(	(	(	N	O
free	JJ	free	free	free	N	I-AdverseReaction
and	CC	and	and	and	N	O
total	JJ	total	total	total	N	I-AdverseReaction
)	)	)	)	)	N	O
values	NNS	values	value	valu	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
APTIOM	NNP	aptiom	aptiom	aptiom	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
changes	NNS	changes	change	chang	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	B-Negation
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
thyroid	JJ	thyroid	thyroid	thyroid	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
tests	NNS	tests	test	test	N	O
suggesting	VBG	suggesting	suggesting	suggest	N	O
hypothyroidism	NN	hypothyroidism	hypothyroidism	hypothyroid	Y	B-AdverseReaction
.	.	.	.	.	N	O

Abnormal	NNP	abnormal	abnormal	abnorm	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
clinically	RB	clinically	clinically	clinic	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
.	.	.	.	.	N	O

